Priority Research Centre for Healthy Lungs, School of Biomedical Sciences and Pharmacy, Hunter Medical Research Institute & University of Newcastle, Callaghan, NSW, Australia.
School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston, Australia.
Curr Opin Pharmacol. 2019 Jun;46:143-149. doi: 10.1016/j.coph.2019.06.003. Epub 2019 Jul 26.
Asthma is a common, heterogeneous and serious disease with high prevalence globally. Poorly controlled, steroid-resistant asthma is particularly important as there are no effective therapies and it exerts substantial healthcare and societal burden. The role of microbiomes, particularly in chronic diseases has generated considerable interest in recent times. Existing evidence clearly demonstrates an association between asthma initiation and the microbiome, both respiratory and gastro-intestinal, although its' roles are poorly understood when assessing the asthma progression or heterogeneity (i.e. phenotypes/endotypes) across different geographical locations. Moreover, modulating microbiomes could be preventive and/or therapeutic in patients with asthma warrants urgent attention. Here, we review recent advances in assessing the role of microbiomes in asthma and present the challenges associated with the potential therapeutic utility of modifying microbiomes in management.
哮喘是一种常见的、异质的、严重的疾病,在全球范围内发病率很高。控制不佳、类固醇耐药的哮喘尤其重要,因为目前尚无有效的治疗方法,它给医疗保健和社会带来了巨大的负担。微生物组在慢性疾病中的作用近年来引起了广泛关注。现有证据清楚地表明,哮喘的发生与微生物组(包括呼吸道和胃肠道微生物组)之间存在关联,尽管在评估不同地理位置的哮喘进展或异质性(即表型/内型)时,其作用尚不清楚。此外,调节微生物组可能对哮喘患者具有预防和/或治疗作用,这值得引起人们的关注。在这里,我们综述了评估微生物组在哮喘中的作用的最新进展,并提出了与改变微生物组在管理中的潜在治疗用途相关的挑战。